Drug
Ak146d1 For
Ak146d1 For: highest development phase Phase 2, developed by Akeso. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK146D1 for injection NCT07669779 | Phase 2 | Advanced Non Small Cell Lung Cancer (NSCLC) |
| AK146D1 for injection NCT07591090 | Phase 2 | Advanced Breast Cancer |
| AK146D1 for injection NCT06929663 | Phase 1 | Advanced Solid Tumors |
Latest
Follow Ak146d1 For on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.